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Abstract: Voltage-gated potassium (KV) channels regulate diverse physiological processes and are an
important target for developing novel therapeutic approaches. Sea anemone (Cnidaria, Anthozoa)
venoms comprise a highly complex mixture of peptide toxins with diverse and selective pharmacology
on KV channels. From the nematocysts of the sea anemone Actinia bermudensis, a peptide that we
named AbeTx1 was purified and functionally characterized on 12 different subtypes of KV channels
(KV1.1–KV1.6; KV2.1; KV3.1; KV4.2; KV4.3; KV11.1; and, Shaker IR), and three voltage-gated sodium
channel isoforms (NaV1.2, NaV1.4, and BgNaV). AbeTx1 was selective for Shaker-related K+ channels
and is capable of inhibiting K+ currents, not only by blocking the K+ current of KV1.2 subtype,
but by altering the energetics of activation of KV1.1 and KV1.6. Moreover, experiments using six
synthetic alanine point-mutated analogs further showed that a ring of basic amino acids acts as a
multipoint interaction for the binding of the toxin to the channel. The AbeTx1 primary sequence is
composed of 17 amino acids with a high proportion of lysines and arginines, including two disulfide
bridges (Cys1–Cys4 and Cys2–Cys3), and it is devoid of aromatic or aliphatic amino acids. Secondary
structure analysis reveals that AbeTx1 has a highly flexible, random-coil-like conformation, but with a
tendency of structuring in the beta sheet. Its overall structure is similar to open-ended cyclic peptides
found on the scorpion κ-KTx toxins family, cone snail venoms, and antimicrobial peptides.
Keywords: sea anemone neurotoxin; Actinia bermudensis; potassium channel; type 6 KV-toxins;
Alanine point mutation
1. Introduction
Voltage-gated potassium (KV) channels regulate diverse physiological processes, including
action potential duration, neuronal excitability, and neurotransmitter release. At present, more than
50 human genes encoding 12 different families of KV channels have been cloned and their structure and
biochemical properties characterized. Because of the importance of mutations that are associated with
pathological disorders, KV channels have become an important target for developing novel therapeutic
approaches and for drug design [1,2]. Since the early 1970′s, toxins have become essential tools in
pharmacological and biochemical studies on KV channels, and from then on, an increasing number of
peptide neurotoxins that specifically target these channels have been discovered [3,4].
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During the course of evolution, scorpions developed a vast array of peptide toxins to increase
hunt, competition, and defense efficiency. Some of these peptides have evolved over time on the
basis of common architectural motifs, displaying convergent molecular determinants and functional
homologies. Scorpion toxins that target K+ channels (KTx) contain about 20–70 amino acids with
2–4 disulfide bridges, and they can be divided into five families: α-KTx, β-KTx, γ-KTx, κ-KTx,
and ε-KTx [5–8]. κ-Hefutoxin 1, from the Asian forest black scorpion Heterometrus fulvipes, was the
first subfamily member of the kappa-toxins (κ-KTx) active on KV channels [7]. Up to date, this family
is subdivided into five subfamilies and comprises more than 20 members [9]. Most of the κ-KTx
toxins show a weak inhibiting activity on Shaker-type K+ channels, KV7.1, and KV10.1, except for
κ-KTx1.3 [7,9–14]. This family of toxins adopts a unique three-dimensional fold of two parallel helices
that are linked by two disulfide bridges (cystine-stabilized α/αmotif) without any β-sheets. Moreover,
some of these peptides share a conserved functional core that is composed of a lysine associated with a
6.6 ± 1 Å distant tyrosine responsible for their binding to KV channels [7,10,11].
Sea anemone venoms are known to contain neurotoxins that are active on voltage-gated sodium
(NaV) channels, Acid-sensitive ion channels (ASIC), and KV channels [15]. The KV-toxins can be
grouped into five structural classes according to their differences in amino acid sequences, disulfide
bridge patterns, and activity profiles, and can affect channels either by blocking the current or
modifying the gating mechanism. Sea anemone type 1, 2, and 5 toxins act solely as pore blocker,
while type 3 toxins inhibit the currents of Shaw- and ERG-related K+ channels by shifting the
voltage-dependence of activation in the positive direction. Type 4 toxins were indirectly assayed
by competitive inhibition of the binding of 125I-α-dendrotoxin [15,16].
Here, we report the biochemical purification and electrophysiological characterization of the first
member of a novel family (Type 6) of sea anemone KV-toxins, from the venom of the sea anemone
Actinia bermudensis. AbeTx1 is a peptide with 17 amino acids and a disulfide bridge connectivity
(Cys1–Cys4 and Cys2–Cys3) that is similar to that of scorpion kappa-toxins (κ-KTx), cone snail toxins
and antimicrobial peptides. It is the shortest sea anemone toxin reported so far, and to the best of our
knowledge, the first sea anemone KV-toxin that has a dual effect on Shaker-type K+ channels activation
kinetics. Furthermore, alanine analogs were used to investigate the contribution of AbeTx1 amino
acids to the molecular mechanism that is involved with KV channels recognition.
2. Results
2.1. Biochemical Properties
A. bermudensis venom was fractionated on a Sephadex G-50 column. The eluted Fraction III
(Figure 1A) was then subjected to a reversed-phase HPLC chromatography, while using a linear
gradient from 10 to 50% of solution B (Figure 1B). AbeTx1 toxin was separated from minor contaminants
after a second rp-HPLC step, under an isocratic condition (9% of solution B) (Figure 1C). AbeTx1
purity was determined by MALDI-TOF analysis. A mass peak with an apex mass of 1889.8 Daltons
was measured (Figure 1D). This experimental mass is in agreement with the calculated theoretical
monoisotopic mass of 1888.875 Da. AbeTx1 amino acids could be entirely sequenced by automated
Edman degradation—RCKTCSKGRCRPKPNCG—without the need for any pre-treatment of the
sample. The protein sequence data reported herein will appear in the UniProt Knowledgebase
(UniProtKB) under accession number C0HJD9.
The presence of four cysteines in AbeTx1 sequence suggests the existence of two disulfide bridges.
Three disulfide connectivity patterns may be inferred and they can be distinguished by cleaving
AbeTx1 with Endopeptidase LysC, which hydrolyzes the peptide bonds at the carboxyl side of lysyl
amino acids (Figure 2A). The molecular masses of the digested fragments were detected as single
charged ions by MALDI-TOF mass spectrometry. Fragment ions were observed at m/z 171.7, 211.8,
378.9, 483.0, 568.0, 716.3, 871.4, 1084.5, 1151.6, 1216.6, 1429.8, and 1712.8 Daltons (data not shown). The
ion at m/z 1151.6 correspond to the digested fragment (TCSKGRCRPK) that contain the second and
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third cysteines (Figure 2B), and an ion at m/z 716.3 correspond to the fragment peptide (RCKPNC)
comprising the first and the fourth cysteines (Figure 2C). The other mass signals that were observed
represented intermediate products of digestion.
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AbeTx1 was obtained after a second reversed-phase HPLC step using isocratic conditions (9% 
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Figure 1. Purification and mass spectrometry characterization of AbeTx1. (A) Gel-filtration
chromatography of A. bermudensis venom. Approximately 3.0 g of venom was injected into a Sephadex
G-50 column, an fractions were eluted with 0.1 M ammonium acetate buffer (pH 7.0) and collected
during UV (280 nm) monitoring. (B) Reversed-phase HPLC chromatogram of fraction III from gel
filtration on a Sephadex G-50 column. The goal toxin is shown with an asterisk. (C) Pure AbeTx1
was obtained after a second reversed-phase HPLC step using isocratic conditions (9% solution B).
(D) MALDI-TOF mass spectra of he HPLC-purified AbeTx1 (m/z of 1889.80 Da).Mar. Drugs 2018, 16, x FOR PEER REVIEW  4 of 20 
 
 
Figure 2. Determination of AbeTx1 cysteine framework. (A) Amino acid sequence obtained by 
Edman degradation. Arrows indicate Endopeptidase LysC cleavage sites. Above the sequence, the 
disulfide bridge pattern is drawn. Cysteines are indicated by numbers (1–4) (B,C) MALDI–TOF mass 
spectra of the digested AbeTx1. Arrows highlight molecular weights and the corresponding 
fragments are shown. Monoisotopic molecular weights were compared with the calculated 
molecular weights. 
Furthermore, to gain insight into the relation between AbeTx1 structure and its functional 
activity, we next looked for its intrinsic secondary structure. Circular dichroism spectra of AbeTx1 
and six alanine point-mutated analogs displayed a characteristic negative band at 200 nm in CD 
Buffer (Figure 3A), and in the presence of large unilamellar vesicles (LUVs) consisting of 
zwitterionic phospholipid (POPC) (Figure 3B) or a mixed phospholipid composition (POPC:POPS) 
with a negative net charge (Figure 3C). Albeit the similarity of all the spectra shapes, we observed 
differences in the spectra intensity, which may indicate different binding affinities. 
 
Figure 3. Circular dichroism (CD) spectra of AbeTx1 and six alanine point-mutated analogs in 
different environmental conditions. (A) CD buffer, (B) CD buffer containing POPC (100 mol%) Large 
Unilamellar Vesicles (LUVs), and (C) CD buffer containing POPC:POPS (80:20 mol%) LUVs. The 
LUVs concentration was fixed at 100 μM. 
Figure 2. Determination of AbeTx1 cysteine framework. (A) Amino acid sequence obtained by Edman
degradation. Arrows indicate Endopeptidase LysC cleavage sites. Above the sequence, the disulfide
bridge pattern is drawn. Cysteines are indicated by numbers (1–4) (B,C) MALDI–TOF mass spectra
of the digested AbeTx1. Arrows highlight molecular weights and the corresponding fragments are
shown. Monoisotopic molecular weights were compared with the calculated molecular weights.
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Furthermore, to gain insight into the relation between AbeTx1 structure and its functional
activity, we next looked for its intrinsic secondary structure. Circular dichroism spectra of AbeTx1
and six alanine point-mutated analogs displayed a characteristic negative band at ≈200 nm in CD
Buffer (Figure 3A), and in the presence of large unilamellar vesicles (LUVs) consisting of zwitterionic
phospholipid (POPC) (Figure 3B) or a mixed phospholipid composition (POPC:POPS) with a negative
net charge (Figure 3C). Albeit the similarity of all the spectra shapes, we observed differences in the
spectra intensity, which may indicate different binding affinities.
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Figure 3. Circula dichroism (CD) spectra of AbeTx1 and six alanine poi t-mutated analogs in differe t
environme tal conditions. (A) CD buffer, (B) CD buffer containing POPC (100 mol%) Large Unilamellar
Vesicles (LUVs), and (C) CD buffer containing POPC:POPS (80:20 mol%) LUVs. The LUVs concentration
was fixed at 100 µM.
The deconvolution of CD spectra (Table 1) shows a high content of random coil-like conformations,
but with a tendency of structuring in beta-sheet. To our knowledge, AbeTx1 structural features are
novel within the already described families of sea anemone KV-channel toxins.
Table 1. Secondary structure analysis of AbeTx1 and six synthetic alanine point mutated analogs fitted
by the CD spectra deconvolution software CDNN 2.1.
WT Arg1Ala Lys3Ala Lys7Ala Arg9Ala Arg11Ala Lys13Ala
Tris Buffer
Helix 14.54 13.38 13.84 14.12 13.08 13.48 13.73
Beta 34.75 34.96 35.83 34.6 35.67 36.03 36.18
Turn 17.54 17.11 17.46 17.26 17.19 17.4 17.52
Random Coil 33.17 34.55 32.87 34.1 34.06 33.09 32.65
POPC
Helix 14.7 13.11 14.03 13.71 13.5 13.54 13.46
Beta 34.09 34.92 34.98 34.29 34.88 35.4 35.97
Turn 17.38 16.98 17.41 17.06 17.15 17.29 17.37
Random Coil 33.92 34.92 33.58 34.94 34.47 33.77 33.20
POPC:POPS
(80:20)
Helix 13.03 13.16 13.63 12.4 13.61 13.71 13.55
Beta 35.32 35.27 36.37 35.39 35.98 35.88 36.62
Turn 17.06 17.11 17.57 16.82 17.46 17.49 17.57
Random Coil 34.59 34.46 32.43 35.39 32.87 32.92 32.27
The AbeTx1 amino acid sequence was used to carry out a similarities search while using
BLAST [17]. Interestingly, our search did not retrieve any significant sequence similarity to the
reported peptide. However, voltage-gated potassium channel toxins from scorpions and Conus
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venoms were found to have a similar cysteine pattern (Figure 4) to that of AbeTx1. All of these
peptides contained four cysteines that were separated by three loops of variable size, and they share a
common three-dimensional Cs α/αmotif (helix-loop-helix fold), where the two α-helices are linked
by the two disulfide bridges [7,9–12,18,19].Mar. Drugs 2018, 16, x FOR PEER REVIEW  6 of 20 
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(A) The alignment is based on the cysteines (dark background). Amino acid identities (black boxes)
and similarities (grey boxes) are shown. %ID is the identity score of the peptide compared to AbeTx1.
(B) Species names and biological targets (IC50 values or % of current inhibition) are depicted.
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2.2. Pharmacological Profile
AbeTx1 was subjected to a screening on a wide range of 15 ion channels. Its activity was
investigated on 12 voltage-gated potassium channels (KV1.1–KV1.6, KV2.1, KV3.1, KV4.2, KV4.3, Shaker
IR, and hERG) and three voltage-gated sodium channels (NaV1.2, NaV1.4, and the insect channel
BgNaV1.1). AbeTx1 showed no activity on NaV channels at 3 µM concentration (Figure 5). Interestingly,
the same concentration could inhibit the current of KV1.1 (83.67± 1.45%), KV1.2 (95.33± 1.45%), KV1.3
(19.67 ± 2.18%), KV1.6 (95.00 ± 2.44%), and Shaker IR (15.50 ± 1.80%) subtypes, while the other KV
channel isoforms from the Shaker (KV1.4 and KV1.5), Shab (KV2.1), Shaw (KV3.1), Shal (KV4.2-4.3),
and Erg (KV11.1) subfamilies are not affected (Figure 5).
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zero-current level.
In order to characterize the potency and selectivity profile, concentration-response curves were
constructed for AbeTx1. IC50 values yielded 671.95 ± 150.31 nanomolar (nM) for KV1.1 (Figure 6A),
167.36± 38.58 for KV1.2 (Figure 7A), and 115.68± 31.44 nM for KV1.6 (Figure 7E). To elucidate whether
AbeTx1 inhibited the current through a physical obstruction of the KV1.1 channel pore or act as a
gating modifier, current-voltage (I–V) experiments were performed. The currents were inhibited at
the test potentials from −90 to 100 mV. The I–V cur e in the control experiments a d in the presence
of native toxin was characterized by a voltage for half-maximal activation (V1/2) of −1.94 ± 1.34 mV
and 17.88 ± 1.26 mV, respectively (Figure 6B). T e V1/2 of activation of KV1. is co sidered to be
statistically significant (p < 0.0001). This shows that the inhibition of KV1.1 channels in the presence
of AbeTx1 (600 nM) is associated with a depolarizing shift in the voltage-dependence of channel
opening (n = 6). Moreover, the toxin-induced inhibition of KV1.1 channels is voltage dependent since
differences in the degree of block could be observed in a range of test potentials (n = 6). At higher
membrane potentials, the reduction of the K+ current by the toxin was decreased from 53.47 ± 5.07%
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at –20 mV to 11.07 ± 1.12% at +70 mV (Figure 6C). Washout experiments allow for us to determine
that AbeTx1 is presumably binding the outer vestibule of the channel since toxin effect is reversible
and current is completely recovered (Figure 6D).
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18.60 ± 1.24 mV and 26.35 ± 1.52 mV, respectively (Figure 7F). The V1/2 of activation of KV1.6 is 
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Figure 6. Electrophysiological characterization of AbeTx1 on KV1.1 isoform. (A) Concentration-
response curve. The curve was obtained by plotti g the percentage blocked current as a function
of increasing toxin conce tra ions, fitted with the Hill equation (solid line). (B) Curr nt-voltage
relationships in control co dition and in the prese ce of AbeTx1 (600 nM). Current traces were evoked
by 10 mV depolarization steps from a holding potential of −90 mV. Open circles indicate the control
condition; closed circles indicate the addition of toxin. The solid lines represent the average Boltzmann
fits in control conditions and in presence of AbeTx1 (600 nM). (C) Percentage of currents inhibition after
application of AbeTx1 (600 nM). The percentage of inhibition was calculated according to the formula
(1 − IToxin/IControl) × 100, where the peak currents in the presence and absence of AbeTx1 (600 nM)
were measured by depolarization to the indicated voltages from a holding potential of −90 mV. Fit line
is from a linear function. (D) Representative experiment of the time course current inhibition with
AbeTx1 (3 µM) and the reversibility hereof. Control (circles), washout (triangle symbols). Plots shown
are a representative of at least three individual experiments.
We also investigated the AbeTx1 mechanism of action on KV1.2 and KV1.6 channel isoforms.
Curre t-voltage (I–V) experiments were performed at the test otentials from −90 to 100 mV and the
inhibition of KV1.2 was not associated with a change in the shape of the I–V relationship. The KV1.2
control curve and the curve in the presence of AbeTx1 (160 nM) were characterized by V1/2 values of
20.72 ± 1.33 mV and 22.82 ± 1.55 mV, respectively (p = 0.3620) (Figure 7B). Moreover, the KV1.6 control
curve and the curve in the presence of toxin (120 nM) were characterized by V1/2 values of 18.60 ±
1.24 mV and 26.35 ± 1.52 mV, respectively (Figure 7F). The V1/2 of activation of KV1.6 is considered to
be statistically significant (p = 0.0168). The K+ current inhibition of both KV isoforms by the toxin was
voltag -independent, sin e the degree of block is not different in t e range of test potentials from −20
to +50 mV (Fig re 7C,G). Th toxin binding on both KV channels is reversible—since the current was
completely recovered upon washout—indicating that the binding site is presumably the outer side of
the channel (Figure 7D,H).
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the average Boltzmann fits in control conditions and in presence of AbeTx1. (C,G) Percentage of 
current inhibition after the application of AbeTx1. The percentage of inhibition was calculated 
according to the formula. (1 − IToxin/IControl) × 100, where the peak currents in the presence and absence 
Figure 7. Electrophysiological experiments of AbeTx1 on KV1.2 and KV1.6 channels. (A,E) Concentration-
response curve. The curve was obtained by plotting the percentage blocked current as a function
of increasing toxin concentrations, fitted with the Hill equation (solid line). (B,F) Current-voltage
relationships in control condition and in the presence of AbeTx1. Current traces were evoked by
10 mV depolarization steps fr m a holding potential of −90 mV. Open circles i dicate the control
condition; closed circles i dicate the additi n of toxi . The solid lines represent the average Boltzmann
fits in control conditions and in presence of AbeTx1. (C,G) Percentage of current inhibition after
the application of AbeTx1. The percentage of inhibition was calculated according to the formula.
(1 − IToxin/IControl) × 100, where the peak currents in the presence and absence of toxin were measured
by depolarization to the indicated voltages from a holding potential of −90 mV. Fit line is from a
linear function. (D,H) Representative experiment of the time course current inhibition with AbeTx1
(3 µM) and the reversibility hereof. Control (circles), washout (triangle symbols). Plots shown are a
representative of at least three individual experiments.
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Competitive binding experiments using tetraethylammonium (TEA) were performed on KV1.1
and KV1.6. First, 200 µM (IC50) TEA was applied to the bath solution and it resulted in a reduction
of KV1.1 current to 52.20 ± 1.74%. Next, AbeTx1 (600 nM) was applied to the bath solution already
containing the TEA and a reduction of 71.20 ± 2.18% was observed (n = 6), indicating that the binding
sites of both ligands are not completely overlapping (Figure 8). Similar experiments were performed
on KV1.6. After apply 920 µM (IC50) of TEA, K+ currents were reduced to 51.50 ± 0.65%. Then, when
AbeTx1 (120 nM) was applied, the reduction of 55.33 ± 2.47% was observed (Figure 8).
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Figure 8. Competition between T AEXT and AbeTx1 on KV1.1 and KV1.6. Shown are the currents for
control, steady-state block by T AEXT (200 µM for KV1.1 and 920 µM for KV1.6) and the subsequent
effect of AbeTx1 (600 nM for KV1.1 and 120 nM for KV1.6) together with tetraethylammonium (TEA).
Currents were evoked by 500 ms depolarization to 0 mV followed by a 500 ms pulse to -50 mV, from a
holding potential of −90 mV.
Furthermore, six synthetic alanine point-mutated analogs were tested on KV1.1 and KV1.6.
arginine at position 1 (Arg1Ala), Lys3Ala, Lys7Ala, Arg9Ala, Arg11Ala, and Lys13Ala were substituted
based on the rationale that a ring of basic amino acids present in various KV-acting toxins plays a
pivotal role in the recognition and interaction with the KV channel outer vestibule. When compared
to native AbeTx1, all alanine substitutions showed a shift of the IC50 values to the micromolar range
when tested on KV1.1. The three alanine analogs Lys3Ala, Lys7Ala, and Arg11Ala showed the most
significant loss of activity (41, 26, and 32-fold, respectively), whereas Arg1Ala, Arg9Ala, and Lys13Ala
induced a milder decrease of blocking activity (3, 6, and 12-fold, respectively). The results from
concentration-response experiments and the Hill coefficient are given in Figure 9. Similar decreased
blocking activity on KV1.6 channel was observed. Arg1Ala and Arg9Ala greatly affect AbeTx1 affinity
(30 and 21-fold, respectively), and Lys3Ala resulted in the most significant decline (156-fold) of
inhibition. Lys7Ala, Arg11Ala, and Lys13Ala induced a moderate reduction on toxin potency (~7 to
10-fold) when compared to wild AbeTx1 (Figure 9). Amino acid Lys-3 has been shown to be the most
important amino acid for AbeTx1 binding to KV1.1 and KV1.6.
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3. Discussion
Proteomics and transcriptomics studies have shown that peptide diversity in sea anemone venoms
is more complex than previously expected, indicating that a great number of new members of known
classes and novel types of toxins remains unexplored [20–22]. Recently, we have structurally and
functionally characterized two new members of sea anemone type 1 toxins, as well as a novel family
(type 5) of KV-toxins, purified from the venom of B. caissarum population from Saint Peter and Saint
Paul Archipelago, Brazil [16,23]. In the present work, we have investigated the neurotoxic components
of A. bermudensis venom, and the first representative member of a novel family of peptide toxins has
been discovered. AbeTx1 was purified by gel filtration and by two reversed-phase chromatography
steps (Figure 1). Homogeneity was confirmed by mass spectrometry analysis, as well as through
the amino acid sequence determination (only one amino acid per cycle of the Edman degradation).
AbeTx1 is a single-chain peptide containing 17 amino acids cross-linked by two disulfide bridges
(Cys1–Cys4 and Cys2–Cys3). Since the primary structure of AbeTx1 has three loops—each one of them
with one lysine—between the four cysteines, we decided to cleavage the peptide using Endopeptidase
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LysC, which hydrolyzes peptide bonds at the carboxyl side of lysyl amino acids (Figure 2). Similar
to AbeTx1, other sea anemone peptides with four cysteines have been purified and functionally
characterized. Sea anemone type 4 KV-toxins is represented by SHTX-I and -II toxins, purified from
the Stichodactyla haddoni body extracts. These peptides have two disulfide bridges that are formed
between the first cysteine and the third cysteine and the second and the fourth [24]. Moreover, by
similarity, the position of the two disulfide bridges in BcgIII 23.41 [25] and U-SHTX-Sdd1 [21] (from
the venom of the Brazilian sea anemones B. cangicum and S. duerdeni, respectively) was assumed to
be the same. BcgIII 23.41 increased the amplitude and duration of the action potentials (a common
feature for NaV-toxins) when being tested on crab leg sensory nerve, while U-SHTX-Sdd1 has no
activity on voltage-gated potassium channels expressed in X. laevis oocytes. Recently, a new peptide
(pi-AnmTX Ugr 9a-1, from the sea anemone Urticina grebelnyi) adopting a unique β-hairpin motif and
with a similar cysteine pattern to SHTX–I and –II, was found to inhibit the transient and the sustained
current of human Acid-sensing Ion Channel 3 [26]. AbeTx1 and Ala-mutant analogs secondary
structure, irrespective of varying the surface charge and hydrophobicity of the environment, shows
a high content of random coil-like conformations, but with a tendency of structuring in beta-sheet
(Figure 3 and Table 1). Interestingly, predictions of the AbeTx1 secondary structure while using the
platforms SCRATCH Protein Predictor [27] and PROCHECK [28] also inferred the same random-coiled
arrangement. Therefore, when considering the elucidation of AbeTx1 primary structure that is
substantially different from the sea anemone KV-toxins that are described above (the highest identity
received was 25%), its unique disulfide bridge pattern, secondary structure elements, and biological
target, we are allowed to classify AbeTx1 as a novel family of potassium channel toxins from sea
anemones, named Type 6 KV-toxins (Figure S1).
Kappa-toxins function was first hypothesized as a potassium channel toxin based on the presence
of a ‘functional dyad’ composed of a lysine associated with a 6.6 ± 1 Å distant tyrosine, being
comparable to other KV-toxins [7,29]. However, since the pharmacological characterization of the
first scorpion κ-KTx toxin, it has been questioned if KV channels are the primary target of these
peptides, since IC50 values ranging from 10 to 217 µM and concentrations up to 500 µM are sometimes
needed to block K+ currents (Figure 4). The present pharmacological characterization showed that
AbeTx1 is active against members of the Shaker-type K+ channels when tested on a wide range of
15 different ion channels, including three voltage-gated sodium channel isoforms. AbeTx1 blocks
KV1.1, KV1.2, KV1.3, KV1.6, and Shaker IR subtypes, but with markedly different potencies (Figure 5).
The electrophysiological experiments revealed a very interesting pattern of affinities towards KV1.1,
KV1.2, and KV1.6, and thus these three isoforms were used to further characterize the effects of the
toxin. KV1.2 and KV1.6 isoforms were the most sensitive to AbeTx1 with an affinity—at nanomolar
concentrations—four-fold higher than KV1.1 channels (Figures 6A and 7A,E). Despite the absence of
the ‘functional dyad’s, generally thought to be responsible for a secondary anchor point to KV channels
and increasing potency [30], AbeTx1 showed the highest affinity for the Shaker-type K+ channels when
compared to other toxins with a similar folding (scorpion κ-KTx toxins and conotoxins) (Figure 4).
The dyad is also not present in OmTx3 (the most potent of the four Om-toxins) because of the lack of
the aromatic amino acid tyrosine [10]. However, as already reported in previous publications [9,12],
there is a discrepancy between the amino acid sequence submitted to the UniProtKB database (P0C1Z4)
and the reported in their publication, which has a tyrosine present at position 5, similar to the other
Om-toxins. Additionally, OcyC8 does not contain the functional dyad proposed for κ-Hefutoxin 1 [7]
and Om-toxins [10], but possesses the amino acid valine at the position corresponding to the tyrosine,
and an arginine instead of a lysine [12].
AbeTx1 slowed the activation kinetics of KV1.1 and KV1.6 channels by shifting—to more positive
voltage potentials—the energy required for channel opening (Figures 6B and 7F), and also showed a
voltage dependence of blockage of KV1.1, becoming progressively less with membrane depolarization
(Figure 6C). To our knowledge, this is the first identified sea anemone toxin that is capable of modifying
the activation kinetics of Shaker-Type K+ channels [15,31,32]. However, some scorpion κ-KTx toxins
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showed similar electrophysiological features. κ-Hefutoxin 1 [7] and OcyC8 [12] also slow the activation
kinetics of Shaker-Type K+ channels (KV1.3 and KV1.1 channels, respectively), whereas HelaTx1 did
not alter the activation kinetics of KV1.1, but it showed a voltage dependence of block. While the
membrane potential becomes more positive, the channel currents blockage decreases, presumably due
to the high content of basic amino acids in HelaTx1 responsible for an electrostatic repulsion between
toxin and channel [9]. Interestingly, AbeTx1 also has a high content of basic amino acids (theoretical
pI of 9.94 vs 10.24 of HelaTx1) and at neutral pH, it has a positive charge of + 5.8, which makes even
more likely the assumption that HelaTx1, as well as AbeTx1 repulsion at higher membrane voltages, is
due to their cationic surface charge (Figure 6C).
Camargos and colleagues [12] propose, based on docking simulations, Hill coefficients and
selective–activity differences, that OcyC8 is not blocking the pore of the channel through a direct
physical obstruction of the channel, but that one OcyC8 molecule binds to one subunit of the K+ channel
leaving the channel pore unbarred, and then a second molecule binds to another subunit, blocking the
channel pore by toxin-toxin interactions. Our data do not directly address the question of whether
KV1.1 blockage by AbeTx1 is direct or indirect, and it needs to be further investigated. However,
the Hill coefficient of AbeTx1—wild-type and—calculated from the fitting of the concentration-effect
curves (Figure 9) is consistent with inhibition by a single toxin molecule. Moreover, a competitive
interaction between TEA applied externally and AbeTx1 was tested based on the rationale that, if both
compounds act on the same site or by a similar mechanism, their co-application will not induce a
supplementary block of the remaining current. However, if they possess different, non-overlapping
binding sites, a potentiation of the blockage effect will be observed. Interestingly, an additional
blockage effect was observed after the co-application of TEA and AbeTx1 on KV1.1, suggesting that
their binding sites are probably only partially overlapping (Figure 8). Since TEA inhibits KV channel
function by binding within the ion conduction pathway, obstructing potassium flow by interacting
simultaneously with the tyrosine side chains of the selectivity filter on all four subunits [33,34],
we might suggest that AbeTx1 is binding to amino acids adjacent to the selectivity filter or even
remotely from the KV1.1 channel inner pore [35–38]. These findings are in agreement with our initial
hypothesis that AbeTx1 is interacting with KV channels isoforms through a multi-point interaction.
On the other hand, AbeTx1 does not modulate the voltage dependence of activation gating of
KV1.2 channel (Figure 7B). Also, it does not show a difference on the percentage-induced block in
a wide voltage range on both KV1.2 and KV1.6 isoforms (Figure 7C,G), and it blocks K+ currents by
binding in a voltage-insensitive manner to the external vestibule (Figure 7D,H), most likely physically
occluding the pore of the channel [39,40]. Therefore, the extensive pharmacological characterization
presented herein (Figures 6–9) lead us to conclude that the shift induced by AbeTx1 in the depolarizing
direction of the steady-state activation curve cannot by itself account for the decrease in current
seen at the tested potentials. In other words, an additional and different mechanism from gating
modification alone should be invoked to explain the observed inhibition. Thus, it can be surmised that
this additional mechanism is a physical pore block.
As a general line of evidence that is obtained experimentally by selected point mutations,
KV-channel toxins are known to interact through a mechanism of action based on a multipoint
interaction [29,41]. Some well-studied toxins have a ring of basic amino acids that play a role in
defining KV channel selectivity and affinity [42–44]. As already mentioned, AbeTx1 has no aromatic
or aliphatic amino acids in its primary sequence to form a ‘functional dyad’, and so, our hypothesis
is that AbeTx1 interacts with KV1.1 and KV1.6 channels through a ring composed of six basic amino
acids (Arg-1, Lys-3, Lys-7, Arg-9, Arg-11, and Lys-13). Thus, we point-mutated each one of the AbeTx1
positively charged amino acids and is substituted by an uncharged alanine, thereby reducing the
number of basic amino acids that interact with specific amino acids of the four α-subunits of the KV
channels, and therefore, decreasing the toxin affinity [44]. As shown in Figure 9, AbeTx1 interact
through a multi-point interaction process, in which each interaction taken individually does not
contribute equally to the binding strength of the peptide, and so, AbeTx1 high-affinity binding results
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from the summed effects of these numerous toxin-channel interactions. In particular, the substitution
of Lys-3 resulted in the most significant loss of activity, suggesting that Lys-3 is a key basic amino acid
that determines AbeTx1 binding to KV channels. The other five mutants (Arg1Ala, Lys7Ala, Arg9Ala,
Arg11Ala, and Lys13Ala) caused different and weaker effects on toxin binding. When comparing their
affinity on both KV isoforms tested, it seems that AbeTx1 may be docked into different orientations
with respect to the KV1.1 and KV1.6 channels, in agreement with TEA binding competition experiments
(Figure 8). Circular dichroism of all synthetic analogs showed similar secondary structures pattern
as native (Figure 3 and Table 1), indicating that the reduced activity of these analogs is probably due
to the loss of their side chains. Also, suggest that the positive electrostatic potential on the surface of
AbeTx1 is likely required for higher binding affinity with KV channels (net charge of wild AbeTx1 is
+5.8 at neutral pH, whereas for the six mutant peptides is + 4.8). However, it should be mentioned that
our results do not address whether other amino acids than those of the ring of basic amino acids might
also be contributing to AbeTx1 binding affinity. For instance, Asn-30 of AgTx2 is reportedly pivotal to
the stabilization of the toxin-channel complex [45], and alanine substitution of Asn-26 in Spinoxin also
resulted in the significant loss of activity [46]. Sea anemone toxin BgK binding site comprises seven
amino acids, including Asn-19, which induced an affinity decrease of 20-fold when substituted by an
alanine [47]. AbeTx1 has an asparagine at position 15 that might contribute to the toxin multi-point
interaction onto the KV channel. Also, AbeTx1 has four cysteines, two glycines, and two prolines that
are characteristic amino acids involved with the conformation of peptides, but might also contribute to
toxin binding. Further research will provide insights into the role of these amino acids.
In conclusion, we have shown the biochemical properties of AbeTx1 as well as its selective activity
toward KV channels and, based on our findings, we propose to classify this toxin as the first member of
a novel family of potassium channel toxins from sea anemones named sea anemone Type 6 KV-toxins.
AbeTx1 is the shortest sea anemone KV-toxin and the first that is capable of blocking the current
of different KV channel isoforms through distinct but cooperative mechanisms of action, i.e. acting
through allosteric effects as well as a pore blocker. Alanine point mutations allow for us to determine
that AbeTx1 interact with KV channels through a ring of six basic amino acids (Arg-1, Lys-3, Lys-7,
Arg-9, Arg-11, and Lys-13) that are involved on its high affinity, although interaction through other
amino acids cannot be discarded.
4. Materials and Methods
4.1. Venom Extraction and Purification of AbeTx1
Specimens of Actinia bermudensis were collected at São Sebastião beach, São Paulo, Brazil.
The venom was obtained by electrical stimulation and fractionated as previously described [23]. Pure
AbeTx1 toxin was obtained after two reversed-phase chromatography on HPLC ÄKTA Purifier system
(GE Healthcare, Uppsala, Sweden), using a semi-preparative CAPCELL PAK C-18 column (1 × 25 cm;
Shiseido Corp., Kyoto, Japan). Solution A was 0.1% TFA in water, solution B was acetonitrile containing
0.1% trifluoroacetic acid (TFA). First, peptide elution was achieved while using a linear gradient from
10% to 50% of solution B at a flow rate of 2.5 mL·min−1. Afterward, an isocratic condition of 9% of
solution B at a flow rate of 1 mL·min−1 was performed using the same column. AbeTx1 protein content
was estimated using the commercial Pierce™ BCA Protein Assay kit (Thermo Scientific, Waltham,
MA, USA) according to the manufacturer’s instruction, and its homogeneity was verified by mass
spectrometry analysis.
4.2. Mass Spectrometry Analysis
Mass spectra were acquired under linear and reflectron modes, using a Bruker Ultraflex II
MALDI-TOF/ TOF controlled by FLEXCONTROL 3.0 software (Bruker Daltonics, Bremen, Germany).
External calibration was performed while using Peptide Standard Calibration II (Bruker Daltonics) and
Peptide Calibration Mix 3 (PepMix3; New England Biolabs, Ipswich, MA, USA) for reflection and linear
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modes, respectively. The matrix, α-cyano-4-hydroxycinnamic acid (Sigma-Aldrich, St. Louis, MO,
USA) was prepared at a concentration of 20 mg·mL−1 in 1:1 acetonitrile containing 0.1% TFA solution.
AbeTx1 solution (1µL) dropped onto the MALDI sample plate (384 positions; Bruker Daltonics) was
added to the matrix solution (1µL) and dried at room temperature. Spectra were analyzed using
thebFLEXANALYSIS 3.0 program (Bruker Daltonics Software).
4.3. AbeTx1 Disulfide Bonds Pattern Determination
AbeTx1 sample was digested with Endopeptidase LysC (Sigma-Aldrich) at 37 ◦C for 30, 60,
and 120 min, in an enzyme:toxin ratio of 1:10, 1:20 and 1:100 (w/w) in Tris-HCl (150 mM, pH 8.5).
Molecular weights of enzymatic fragments were acquired, as described before, using a Bruker Ultraflex
II MALDI-TOF/TOF (Bruker Daltonics).
4.4. Amino Acid Sequence Determination
Native AbeTx1 (100 pmol) was sequenced by Edman degradation using the automated
PPSQ-33A protein sequencer (Shimadzu, Kyoto, Japan) coupled to reversed-phase separation of
phenylthiohydantoin (PTH)-amino acids on a WAKOSIL-PTH (4.6 × 250 mm) column (Wako, Osaka,
Japan), according to the manufacturer’s instructions.
4.5. Large Unilamellar Vesicles (LUVs) Preparation
The lipid stock solutions in chloroform were transferred to glass tubes in the appropriate
proportions at a final concentration of 5 mM and the solvent was evaporated under N2 flow.
The samples were dried under vacuum for 3 h to remove solvent traces. The lipid films were
hydrated with CD buffer (5 mM Tris and 150 mM NaF, pH 7.4, adjusted with H3BO3). The lipid
suspensions were thoroughly vortex mixed and submitted to 31 extrusions through two-stacked 100 nm
polycarbonate membranes using an Avanti mini-extruder (Avanti Polar Lipids, Alabaster, Alabama,
USA). The phospholipid content was measured by the Rouser method [48]. The lipid films were
prepared in the following compositions: (A) 100 mol% of 1-palmitoyl-2-oleoylphosphatidylcholine
(POPC) and (B) 80:20 mol% of POPC: 1-palmitoyl-2-oleoylphosphatidylserine (POPS).
4.6. Circular Dichroism
Circular Dichroism (CD) experiments were performed in a Chirascan-plus qCD (Applied
Photophysics Ltd, Leatherhead, Surrey, UK) in a 0.1 cm path length quartz cuvette. AbeTx1 and
analogs (10 µM) were added in a cuvette containing CD Buffer or CD Buffer and POPC (100 mol%)
or POPC: POPS (80:20 mol%) LUVs (100 µM). The CD spectra were collected from 190 to 260 nm,
at 25 ◦C, with a bandwidth of 1 nm, step of 1 nm, time-per-point of 0.1 s, and current time-per-point
of 0.1 s. Each CD spectra was averaged over eight repetitions. The observed ellipticity θ (mdeg) was
converted to mean amino acid ellipticity θ (deg·cm2·dmol−1) after the baseline correction, using the
relationship: [θ] = (100.θ)/(l.c.n). Where l is the path length in centimeters, c is peptide millimolar
concentration and n the number of peptide amino acids. A lipid baseline spectrum was subtracted
from all peptide/lipid spectra.
4.7. AbeTx1 Analogs Synthesis–Alanine Substitution
Six synthetic AbeTx1 analogs (1–4 mg) were purchased from GenScript Corporation (NY) with
purity higher than 98% and the same disulfide bonds pattern (Cys1–Cys4 and Cys2–Cys3) as native
AbeTx1. Positively charged amino acids (Arg1, Lys3, Lys7, Arg9, Arg11, and Lys13) were substituted
by an uncharged alanine. Analogs are designated by three letters and number indicating the identity
and position of the six substituted amino acids, followed by three letters indicating the identity of the
replacement amino acid. Quality control of the six analogs was confirmed by HPLC, mass spectrometry,
and Edman degradation sequencing, as described above.
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4.8. Heterologous Expression of Ion Channels in Xenopus Laevis Oocytes
The pharmacological effect of AbeTx1 was analyzed by heterologous expression of 12 voltage-
gated potassium channels isoforms (rKV1.1, Genbank NM173095; rKV1.2, Genbank NM012970;
hKV1.3, Genbank L23499; rKV1.4,Genbank NM012971; rKV1.5, Genbank NM012972; rKV1.6, Genbank
NM575671; Shaker IR from Drosophila melanogaster, Genbank CG12348; rKV2.1, Genbank NM013186;
hKV3.1, Genbank NM004976; rKV4.2, Genbank NM031730; rKV4.3, Genbank NM031739 and hERG,
Genbank NM000238), and three voltage-gated sodium channel subtypes (rNaV1.2, Genbank NM012647;
rNaV1.4, Genbank M26643 and BgNaV1.1, from Blattella germanica) (r, rat; h, human) in oocytes from
Xenopus laevis. The linearized plasmids were transcribed using a T7 or SP6 mMESSAGE-mMACHINE
transcription kit (Life Technologies, Austin, TX, USA). Oocytes were injected with 20–50 nL of cRNA
at a concentration of 1 ng·nL−1 using a microinjector (Drummond Scientific, Broomall, PA, USA).
The oocytes were stored for 1–3 days at 16 ◦C until sufficient expression of voltage-gated ion channels
was achieved. Oocytes were maintained in an ND96 solution (in mM: 96 NaCl, 2 KCl, 1.8 CaCl2,
2 MgCl2 and 5 HEPES; pH 7.4), supplemented with 50 µg·mL−1 gentamicin sulfate.
4.9. Electrophysiological Recordings
Two-electrode voltage-clamp recordings were performed at room temperature (18–22 ◦C) using
a Geneclamp 500 amplifier (Molecular Devices, Sunnyvale, CA, USA) controlled by a pClamp data
acquisition system (Axon Instruments, Union City, CA, USA). ND96 was used as bath solution.
Whole-cell currents from oocytes were recorded 1–3 days after injection. Voltage and current electrodes
were filled with KCl (3 M). The resistance of both electrodes was kept between 0.8–1.0 MΩ. The elicited
currents were filtered at 0.5 or 2 kHz using a four-pole low-pass Bessel filter. Leak subtraction
was performed using a -P/4 protocol. KV1.1-KV1.6 and Shaker IR currents were evoked by 500 ms
depolarization to 0 mV, followed by a 500 ms pulse to −50 mV, from a holding potential of −90 mV.
KV2.1, KV3.1, KV4.2, and KV4.3 currents were elicited by 500 ms pulses to + 20 mV from a holding
potential of −90 mV. Current traces of hERG channels were elicited by applying a +40 mV pulse
for 2.5 s, followed by a step to −120 mV for 2.5 s. Sodium current traces were evoked by 100 ms
depolarization steps from a holding potential of −90 mV to 0 mV. Concentration-response curves
were constructed by adding different AbeTx1 or analogs concentrations directly to the bath solution.
The percentage of the KV blockade was plotted against the logarithm of the applied concentrations
and fitted with the Hill Equation (1):
y = 100/[1 + (IC50/[toxin]) × h] (1)
where y is the amplitude of the toxin-induced effect, IC50 is the toxin concentration at half-maximal
efficacy, [toxin] is the toxin concentration, and h is the Hill coefficient. To investigate the effects on the
voltage dependence of activation, current traces were evoked by 10 mV depolarization steps from a
holding potential of −90 mV. Data were normalized to the maximal K+ current amplitude, plotted
against prepulse potential, and fitted using the Boltzmann Equation (2):
IK/Imax = [1 + (exp(Vg − V)/k] − 1 (2)
where Imax represents maximal potassium current (IK), Vg is the voltage corresponding to
half-maximal current, and k is the slope factor. Each experimental data represents mean ± standard
error of at least three oocytes (n ≥ 3) from different frogs. Effect of the toxin on current-voltage
experiments was statistically examined by comparing the control condition and the presence of toxin
using the Student’s paired t-test. P-values < 0.05 are considered to be statistically significant. Data
were analyzed using Clampfit 10.4 (Molecular Devices, Sunnyvale, CA, USA) and Origin v8.1 software
(Origin Lab, Northampton, MA, USA), under the institutional license of the University of São Paulo.
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4.10. Bioinformatics
BLAST searches [17] using AbeTx1 amino acid sequence as the query sequence were
performed against the data sets of GenBank and Protein Knowledgebase (UniProtKB). A multiple
sequence alignment of AbeTx1, neurotoxins from marine cone snails, and kappa-toxin subfamily
members was done with ClustalW2 [49]. Sequences analyzed were that of Hefutoxin 1 and 2
(Swiss-Prot P82850 and P82851, respectively–from Heterometrus fulvipes) [7]; Hefutoxin 3 (Swiss-Prot
P83655–H. spinifer) [11]; HelaTx1 (Swiss-Prot P0DJ41–H. laoticus) [9]; OmTx1–4 (Swiss-Prot P0C1Z3
and P0C1Z4, respectively–Opisthacanthus madagascariensis) [10]; OcyC8 (Swiss-Prot P86110) and OcyC9
(Swiss-Prot C5J893) (O. cayaporum) [12]; HSP009C, HSP053C.1 (HeTx203), HSP053C.2 (HeTx204),
HSP040C.1, HSP040C.3, HSP040C.4, HSP040C.5 and HSP040C.2 (Swiss-Prot P0DJ33–P0DJ40,
respectively—H. petersii) [13,18]; and, flf14a–c (Swiss-Prot P84705–P84707, respectively—Conus
floridanus floridensis) [19].
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/10/360/s1,
Figure S1: Multiple sequence alignment of sea anemone KV toxins.
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